Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
We performed a prospective study to examine the genetic effect on the response to a calcium (Ca) channel blocker, azelnidipine and an ACE inhibitor, temocapril treatment in patients with hypertension, as a part of the prior clinical trial, the Azelnidipine and Temocapril in Hypertensive Patients wit...
Main Authors: | Ken Sugimoto, Tomohiro Katsuya, Kei Kamide, Tomomi Fujisawa, Izumi Shimaoka, Mitsuru Ohishi, Ryuichi Morishita, Toshio Ogihara, Hiromi Rakugi |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2010-01-01
|
Series: | International Journal of Hypertension |
Online Access: | http://dx.doi.org/10.4061/2010/196307 |
Similar Items
-
ANRIL: Molecular Mechanisms and Implications in Human Health
by: Ada Congrains, et al.
Published: (2013-01-01) -
Which strategy in inhibition of the renin-angiotensin system is the most efficient for heart failure?
by: Toshio Ogihara, et al.
Published: (2008-09-01) -
Vascular microarray profiling in two models of hypertension identifies caveolin-1, Rgs2 and Rgs5 as antihypertensive targets
by: Wilson Susan R, et al.
Published: (2007-11-01) -
Clinical use of azelnidipine in the treatment of hypertension in Chinese patients
by: Chen BL, et al.
Published: (2015-02-01) -
Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage
by: Puranik Amrutesh S, et al.
Published: (2010-12-01)